A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C—C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double‐blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatology
Main Authors: Friedman, Scott L., Ratziu, Vlad, Harrison, Stephen A., Abdelmalek, Manal F., Aithal, Guruprasad P., Caballeria, Juan, Francque, Sven, Farrell, Geoffrey, Kowdley, Kris V., Craxi, Antonio, Simon, Krzysztof, Fischer, Laurent, Melchor‐Khan, Liza, Vest, Jeffrey, Wiens, Brian L., Vig, Pamela, Seyedkazemi, Star, Goodman, Zachary, Wong, Vincent Wai‐Sun, Loomba, Rohit, Tacke, Frank, Sanyal, Arun, Lefebvre, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947654/
https://ncbi.nlm.nih.gov/pubmed/28833331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29477
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados